XML 13 R4.htm IDEA: XBRL DOCUMENT v3.22.1
Consolidated Statements of Income (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Income Statement [Abstract]    
Net revenue $ 482,229 $ 446,753
Operating expenses:    
Practice salaries and benefits 343,155 319,012
Practice supplies and other operating expenses 28,489 22,212
General and administrative expenses 61,287 66,516
Depreciation and amortization 8,769 8,031
Transformational and restructuring related expenses 1,421 4,878
Total operating expenses 443,121 420,649
Income from operations 39,108 26,104
Investment and other income 875 5,967
Interest expense (11,818) (17,645)
Loss on early extinguishment of debt (57,016) (14,532)
Equity in earnings of unconsolidated affiliate 505 495
Total non-operating expenses (67,454) (25,715)
Income (loss) from continuing operations before income taxes (28,346) 389
Income tax benefit (provision) 7,401 4,955
Income (loss) from continuing operations (20,945) 5,344
Income (loss) from discontinued operations, net of tax (247) 12,290
Net income (loss) (21,192) 17,634
Net loss attributable to noncontrolling interest 4 8 [1]
Net income (loss) attributable to Mednax, Inc. $ (21,188) $ 17,642
Income (loss) from continuing operations:    
Basic $ (0.25) $ 0.06
Diluted (0.25) 0.06
Income (loss) from discontinued operations:    
Basic 0.15
Diluted 0.15
Net income (loss) attributable to Mednax, Inc.:    
Basic (0.25) 0.21
Diluted $ (0.25) $ 0.21
Weighted average common shares:    
Basic 85,405,000 84,526,000
Diluted [2] 85,405,000 85,491,000
[1] Net loss component is presented within retained deficit on the consolidated balance sheet as the balance is immaterial.
[2] Due to a loss from continuing operations for the three months ended March 31, 2022, no incremental shares are included because the effect would be antidilutive.